Overview Dividends

(ANRO) Alto Neuroscience - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US02157Q1094

Antidepressant, Cognitive, Schizophrenia, Depression, Clinical

Pharmaceuticals
Market Cap in USD: 514m
IPO / Inception: 2024-02-02
Return 12m vs S&P 500: 196%

EPS (Earnings per Share)

EPS (Earnings per Share) of ANRO over the last years for every Quarter: "2021-09": null, "2022-09": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": -7.77, "2024-03": -0.76, "2024-06": -0.6, "2024-09": -0.62, "2024-12": -0.52, "2025-03": -0.56, "2025-06": -0.65, "2025-09": -0.52, "2025-12": 0,
EPS CAGR: 1042.37%
EPS Trend: 68.1%
Last SUE: 0.31
Qual. Beats: 0

Revenue

Revenue of ANRO over the last years for every Quarter: 2021-09: null, 2022-09: null, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.372, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.394, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: null,
Rev. CAGR: 0.00%
Rev. Trend: 7.2%
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 94.2%
Value at Risk 5%th 141%
Relative Tail Risk -8.96%
Reward TTM
Sharpe Ratio 1.41
Alpha 224.06
CAGR/Max DD -0.03
Character TTM
Hurst Exponent 0.459
Beta 1.033
Beta Downside 1.756
Drawdowns 3y
Max DD 91.74%
Mean DD 61.48%
Median DD 72.25%

Description: ANRO Alto Neuroscience December 22, 2025

Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharma firm founded in 2019 and based in Mountain View, California, focused on small-molecule therapeutics for neuropsychiatric disorders.

The company’s pipeline consists of five candidates: ALTO-100 (Phase 2b for bipolar depression), ALTO-300 (Phase 2b for major depressive disorder), ALTO-101 (Phase 2 proof-of-concept for cognitive impairment in schizophrenia), ALTO-203 (Phase 2 POC for MDD with high anhedonia), and ALTO-202 (Phase 1 for MDD as an oral GluN2B antagonist).

Key sector drivers include a global antidepressant market valued at roughly $30 billion and a growing demand for novel mechanisms of action, while historical Phase 2 success rates in CNS therapeutics hover around 30 %, underscoring the risk-reward profile of Alto’s programs. As of the latest filing, the company reported a cash runway of about $45 million, giving it roughly 12-month liquidity at its current burn rate of $15 million per quarter.

For a deeper, data-rich perspective on Alto’s valuation and comparable peers, you might explore the analyst tools on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-62.3m TTM) > 0 and > 6% of Revenue (6% = 23.6k TTM)
FCFTA -0.37 (>2.0%) and ΔFCFTA -11.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 33.1k% (prev 45.6k%; Δ -12.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.36 (>3.0%) and CFO -53.3m > Net Income -62.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 15.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (27.1m) change vs 12m ago 0.54% (target <= -2.0% for YES)
Gross Margin -53.55% (prev -31.45%; Δ -22.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.23% (prev 0.19%; Δ 0.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -26.96 (EBITDA TTM -59.4m / Interest Expense TTM 2.23m) >= 6 (WARN >= 3)

Altman Z'' -6.17

(A) 0.89 = (Total Current Assets 139.4m - Total Current Liabilities 9.04m) / Total Assets 147.0m
(B) -1.26 = Retained Earnings (Balance) -185.5m / Total Assets 147.0m
warn (B) unusual magnitude: -1.26 — check mapping/units
(C) -0.35 = EBIT TTM -60.0m / Avg Total Assets 169.3m
(D) -5.23 = Book Value of Equity -185.4m / Total Liabilities 35.4m
Total Rating: -6.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 44.20

1. Piotroski 0.0pt
2. FCF Yield -13.34%
3. FCF Margin data missing
4. Debt/Equity 0.25
5. Debt/Ebitda 1.86
7. RoE -47.39%
8. Rev. Trend 7.19%
9. EPS Trend 68.09%

What is the price of ANRO shares?

As of January 07, 2026, the stock is trading at USD 15.08 with a total of 418,895 shares traded.
Over the past week, the price has changed by -15.94%, over one month by +8.96%, over three months by +130.58% and over the past year by +247.47%.

Is ANRO a buy, sell or hold?

Alto Neuroscience has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy ANRO.
  • Strong Buy: 6
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ANRO price?

Issuer Target Up/Down from current
Wallstreet Target Price 31.1 106.4%
Analysts Target Price 31.1 106.4%
ValueRay Target Price 18 19.4%

ANRO Fundamental Data Overview January 07, 2026

Market Cap USD = 513.5m (513.5m USD * 1.0 USD.USD)
P/B = 4.62
Beta = None
Revenue TTM = 394.0k USD
EBIT TTM = -60.0m USD
EBITDA TTM = -59.4m USD
Long Term Debt = 22.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.12m USD (from shortTermDebt, last quarter)
Debt = 27.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -110.3m USD (from netDebt column, last quarter)
Enterprise Value = 403.2m USD (513.5m + Debt 27.5m - CCE 137.8m)
Interest Coverage Ratio = -26.96 (Ebit TTM -60.0m / Interest Expense TTM 2.23m)
FCF Yield = -13.34% (FCF TTM -53.8m / Enterprise Value 403.2m)
FCF Margin = -13.7k% (FCF TTM -53.8m / Revenue TTM 394.0k)
Net Margin = -15.8k% (Net Income TTM -62.3m / Revenue TTM 394.0k)
Gross Margin = -53.55% ((Revenue TTM 394.0k - Cost of Revenue TTM 605.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.74 (Enterprise Value 403.2m / Total Assets 147.0m)
Interest Expense / Debt = 2.36% (Interest Expense 650.0k / Debt 27.5m)
Taxrate = 100.0% (out of range, set to none) (-61.4m / -61.4m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 15.42 (Total Current Assets 139.4m / Total Current Liabilities 9.04m)
Debt / Equity = 0.25 (Debt 27.5m / totalStockholderEquity, last quarter 111.6m)
Debt / EBITDA = 1.86 (negative EBITDA) (Net Debt -110.3m / EBITDA -59.4m)
Debt / FCF = 2.05 (negative FCF - burning cash) (Net Debt -110.3m / FCF TTM -53.8m)
Total Stockholder Equity = 131.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.35% (Net Income -62.3m / Total Assets 147.0m)
RoE = -47.39% (Net Income TTM -62.3m / Total Stockholder Equity 131.4m)
RoCE = -39.03% (EBIT -60.0m / Capital Employed (Equity 131.4m + L.T.Debt 22.4m))
RoIC = -41.4k% (out of range, set to none) (EBIT -60.0m / (Assets 147.0m - Curr.Liab 9.04m - Cash 137.8m))
WACC = 9.32% (E(513.5m)/V(541.0m) * Re(9.82%) + (debt cost/tax rate unavailable))
Discount Rate = 9.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.41%
Fair Price DCF = unknown (Cash Flow -53.8m)
EPS Correlation: 68.09 | EPS CAGR: 1042 % | SUE: 0.31 | # QB: 0
Revenue Correlation: 7.19 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.48 | Chg30d=N/A | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-2.13 | Chg30d=N/A | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=+0.0%

Additional Sources for ANRO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle